MD, PhD, Professor, Dr. Fedorenko: New approach of treatment for patients with Multiple Sclerosis

HOW TO APPLY FOR HSCT:
Complete our questionnaire, describing your previous treatment and current functional status, to define whether HSCT is a meaningful and safe treatment option for you.
This online form must be accompanied by the report of last MRI (Please attach only report, no MRI images are required)

CONTENT:

SYSTEMIC AUTOIMMUNE DISEASE - MULTIPLE SCLEROSIS

• Prevent further decrease in the quality of your life

- It is a chronic inflammatory disorder of the central nervous system, caused by autoimmune reactivity of T-cells towards components of neural cells.

- The disease progresses slowly and, at the end, the patient is essentially confined to a wheelchair.

• Leave a constant need for expensive and ineffective therapy.

- Modified Therapy helps to limit acute manifestations of the disease, but it cannot stop its progression and, in most cases, it does not provide a stable long-term effect.

- MS progression inevitably leads to impairment of the patient's ability to move, sensitive disturbances and cognitive impairment.

NON-EFFECTIVE TREATMENT:

• Decreasing the rate of inflammation

• Decreasing the number/size of lesions in CNS

• Decreasing the number of relapses per year

• And other surrogate goals of modified therapy

EFFECTIVE TREATMENT OF SYSTEMIC AUTOIMMUNE DISEASE - MULTIPLE SCLEROSIS

1. Stop progression for years

2. Prevent irreversible CNS damage and critical disability

3. Improve significantly neurological deficit for years
• HSCT for MS is based on the rationale of using chemotherapy for ablation of an aberrant, (self-reactive) immune system and regeneration of a new self-tolerant immune system from HSCT.

• HSCT is a new and promising treatment strategy in MS (over 1500 HSCT all over the world), but TRM rate is 3 – 8% for myeloablative protocols.

• The use of less intensive conditioning regimens is supported by the suggestion that HSCT is not only an immunosuppressive therapy, but also could have an immunomodulatory component and low-intensity lymphoablative regimens can be associated with similar outcome results, but presented less toxicity when compared with myeloablative regimens.

• The rationale of using HSCT in MS is to find the best balance between toxicity and safety and to improve long-term outcome of treatment.

THEORY OF TREATMENT INTENSIFICATION:

• Dose Intensification

• Dose Density

• Zone of Low Effectiveness (DMD)

LONGITUDINAL SCHEME

• AHSCT for AID - Evolution from toxicity to safety and better outcomes

SUMMARY AND RESULTS

• Early transplantation, which demonstrates potential to stop disease progression and to prevent disability formation in 92% of patients, appears to be most promising treatment strategy in MS

• The favorable factors for HSCT in MS are: early transplantation (EDSS is lower 3.5), below 30 years old, disease duration is less than 5 years, relapsing-remitting type. Presence of Gd+ lesions, gender, ATG using and QoL parameters before HSCT do not influence on EFS

• HSCT can be used for PPMS and SPMS
• The vast majority of the adverse events as a result of HSCT last for a short period of time and can be controlled. Long-term side effects should be observed and analyzed carefully.

• HSCT was accompanied by a significant improvement in patients quality of life and symptoms with statistically significant changes in the majority of PRO parameters

HISTORY OF MEDICAL INSTITUTION:

• The Department of Hematology and Cellular Therapy created in 2003

• Transplantology Department was created in 2005

• The first HSCT for MS was performed in 2005

• More than 2500 HSCT for hematological malignancies and autoimmune diseases have been performed since 2005

• Prof. A. Novik – the first Chief of the Department and the pioneer of HSCT for MS in Russia
INTERNATIONAL CONFERENCE IN MOSCOW, RUSSIA.

• Sharing the experience in Stem Cell Transplantation for Autoimmune Diseases

This video was recorded specially for online event

[chrisismail]

He is THE BEST!! such a caring Dr and team!!! My wife got trwated by his team 2.5 yrs ago, has been stable since treatment

[ahmadmagdy]

Thanks to dr Fedorenko, Anastasia and all the medical team!

[darianikolenko]

I had treatment in 2014. All I can say is THANK YOU

[squiddlesmcdiddles]

Thank You Dr Federenko, Anastasia & all of the wonderful team in Russia. I had treatment NOV 2020 It was the best decision I ever made :-)

[ivonna.tinkle]

Thank you Dr. F! I had HSCT July 2018.

[niceal]

I had treatment in 2021. All I can say is THANK YOU

[janahorvatova]

Zdravím ja bisomsa chcel spýtať moja celá má 15 tokov či steto už mali pacientku vo jej rokovh

[petvuk]

Why all the attention goes to MS?
When Will you adapt the HSCT protocol to optimise it for rheumatic diseases?! Surely this protocol is not the best for rheumatic, as the success is quite low. And lupus, Sjogrens etc have inflammation so its obviosly not the same reason for low success as with too late in SPMS or simply PPMS.
please, work on Your protocol for other diseases, we matter too, why everyone just talks about MS.

[angelbabycards]

Honestly, It is now irresponsible to see a myriad of people, experiencing efficacy with HSCT, but the procudure continues to be denied in the US, literally for at least One Decade. Meanwhile, people such as Sandra Blair, simply spend a week or so in Russia, they come back, they begin to return to near normal function, dance on Dancing With The Stars, while the rest of us here in The States, prepare for Wheelchairs and Hospital Beds. Question: Is this truly the 1st World Country you thought it once was... ??

Getting ready to gather the cash I need to have the stem cell procedure in Mexico, and that's that! 😊